Free Trial
NASDAQ:BCPC

Balchem Q1 2025 Earnings Report

Balchem logo
$161.31 -1.79 (-1.10%)
As of 04:00 PM Eastern

Balchem EPS Results

Actual EPS
N/A
Consensus EPS
$1.12
Beat/Miss
N/A
One Year Ago EPS
N/A

Balchem Revenue Results

Actual Revenue
N/A
Expected Revenue
$245.70 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Balchem Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, April 24, 2025
Conference Call Time
11:00AM ET

Conference Call Resources

Remove Ads

Balchem Earnings Headlines

DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Sidoti Reaffirms Their Hold Rating on Balchem (BCPC)
See More Balchem Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Balchem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Balchem and other key companies, straight to your email.

About Balchem

Balchem (NASDAQ:BCPC) develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

View Balchem Profile

More Earnings Resources from MarketBeat